Comparative bioavailability of single-dose methylphenidate from a multilayer-release bead formulation and an osmotic system: A two-way crossover study in healthy young adults

Clinical Therapeutics

Volumn 30, Issue 1, 2008, Pages 59-69

  Reiz, Joseph L ^a   Donnelly, Graeme A E ^a   Michalko, Kenneth ^a  

^a PURDUE PHARMA L P   (United States)

Author keywords

ADHD.; methylphenidate; pharmacokinetics

Indexed keywords

BIPHENTIN; METHYLPHENIDATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CATHETER SITE PAIN; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MONITORING; FEMALE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LABORATORY TEST; MALE; NORMAL HUMAN; PAIN; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; URINALYSIS;

ADOLESCENT; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METHYLPHENIDATE; OSMOTIC PRESSURE;

EID: 39749201153     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.01.002     Document Type: Article

References (30)

1. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41 (2002) 26S-49S Suppl
2. CADDRA Guidelines Steering Committee. Guidelines for the Diagnosis and Management of ADHD (2005), Ont: Canadian ADD Resource Alliance, Toronto
3. Schachar R, Ickowicz A, Crosbie J, et al. Cognitive and behavioural effects of multilayer-release methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. In press.
4. Jain U., Hechtman L., Weiss M., et al. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: Results of a double-blind, placebo-controlled crossover study. J Clin Psychiatry 68 (2007) 268-277
5. Weiss M., Hechtman L., Turgay A., et al. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 17 (2007) 675-688
6. Wolraich M., Greenhill L., Pelham W., et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 108 (2001) 883-892
7. Swanson J., Gupta S., Lam A., et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: Proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 60 (2003) 204-211
8. Biederman J., Mick E., Surman C., et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder [published correction appears in Biol Psychiatry. 2007;61:1402]. Biol Psychiatry 59 (2006) 829-835
9. Quinn D., Bode T., Reiz J., et al. Single-dose pharmacokinetics of multilayer-release methylphenidate and immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. J Clin Pharmacol 47 (2007) 760-766
10. Patrick K., González M., Straughn A., and Markowitz J. New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder [published correction appears in Expert Opin Drug Deliv. 2005;2:417]. Expert Opin Drug Deliv 2 (2005) 121-143
11. Concerta. Compendium of Pharmaceuticals and Specialties. 42nd ed (2007), Ont: Canadian Pharmacists Association, Ottawa 581-585
12. Modi N., Lindemulder B., and Gupta S. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. J Clin Pharmacol 40 (2000) 379-388
13. Markowitz J., Straughn A., Patrick K., et al. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet 42 (2003) 393-401
14. González M., Pentikis H., Anderl N., et al. Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 40 (2002) 175-184
15. Swanson J., Lerner M., Wigal T., et al. The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. J Atten Disord 6 Suppl 1 (2002) S73-S88
16. Swanson J., Wigal S., Wigal T., et al., for the COMACS Study Group. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the COMACS Study). Pediatrics 113 (2004) e206-e216
17. Lopez F., Silva R., Pestreich L., and Muniz R. Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day [published corrections appear in Paediatr Drugs. 2003;5:661 and Paediatr Drugs. 2003;5:832]. Paediatr Drugs 5 (2003) 545-555
18. Silva R., Muniz R., Pestreich L., et al. Efficacy of two long-acting methylphenidate formulations in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting. J Child Adolesc Psychopharmacol 15 (2005) 637-654
19. Sonuga-Barke E., Swanson J., and Hunt J. ADHD impact and treatment across the day: A Pan European study. Presented at: 54th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (October 23-28, 2007) Boston, Mass. Abstract
20. Health Products and Food Branch Guidance Document. Guidance for Industry. Conduct and analysis of bioavailability and bioequivalence studies-Part B: Oral modified release formulations. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/bio/bio-b_e.html. Accessed November 27, 2007.
21. Wigal S., Sanchez D., DeCory H., et al. Selection of the optimal dose ratio for a controlled-delivery formulation of methylphenidate. J Appl Res 3 (2003) 46-63
22. Patrick K., Straughn A., Jarvi E., et al. The absorption of sustained-release methylphenidate formulations compared to an immediate-release formulation. Biopharm Drug Dispos 10 (1989) 165-171
23. Pelham W., Gnagy E., Burrows-Maclean L., et al. Once-a-day Con-certa methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107 (2001) e105
24. Pelham W., Gnagy E., Chronis A., et al. A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/ hyperactivity disorder. Pediatrics 104 (1999) 1300-1311
25. Spencer T., Biederman J., Ciccone P., et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 163 (2006) 387-395
26. Volkow N., Wang G., Fowler J., et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 155 (1998) 1325-1331
27. Vitiello B., Severe J., Greenhill L., et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: Lessons from the MTA. J Am Acad Child Adolesc Psychiatry 40 (2001) 188-196
28. Swanson J., Lerner M., Wigal T., et al. The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. J Atten Disord 6 (2002) S73-S88
29. Modi N., Wang B., Hu W., and Gupta S. Effect of food on the pharmacokinetics of osmotic controlled release methylphenidate HCl in healthy subjects. Biopharm Drug Dispos 21 (2000) 23-31
30. Biphentin. Compendium of Pharmaceuticals and Specialties. 42nd ed (2007), Ont: Canadian Pharmacists Association, Ottawa 358-362